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A disease spectrum for ITPA variation:




Human ITPase (encoded by the ITPA gene) is a protective enzyme which acts to exclude noncanonical (deoxy)
nucleoside triphosphates ((d)NTPs) such as (deoxy)inosine 5′-triphosphate ((d)ITP), from (d)NTP pools. Until the last
few years, the importance of ITPase in human health and disease has been enigmatic. In 2009, an article was
published demonstrating that ITPase deficiency in mice is lethal. All homozygous null offspring died before
weaning as a result of cardiomyopathy due to a defect in the maintenance of quality ATP pools. More recently, a
whole exome sequencing project revealed that very rare, severe human ITPA mutation results in early infantile
encephalopathy and death. It has been estimated that nearly one third of the human population has an ITPA status
which is associated with decreased ITPase activity. ITPA status has been linked to altered outcomes for patients
undergoing thiopurine or ribavirin therapy. Thiopurine therapy can be toxic for patients with ITPA polymorphism,
however, ITPA polymorphism is associated with improved outcomes for patients undergoing ribavirin treatment.
ITPA polymorphism has also been linked to early-onset tuberculosis susceptibility. These data suggest a spectrum of
ITPA-related disease exists in human populations. Potentially, ITPA status may affect a large number of patient
outcomes, suggesting that modulation of ITPase activity is an important emerging avenue for reducing the number
of negative outcomes for ITPA-related disease. Recent biochemical studies have aimed to provide rationale for clinical
observations, better understand substrate selectivity and provide a platform for modulation of ITPase activity.
Keywords: ITPA, ITPase, Inosine, ITP, Ribavirin, Azathioprine, Thiopurine, Hepatitis C, Infantile encephalopathy,
Tuberculosis
Background
Inosine triphosphate pyrophosphatase (ITPase) has a
critical role in sanitizing nucleotide pools by removing
(deoxy)nucleoside triphosphates ((d)NTPs) containing
noncanonical purines [1–7]. ITPase is a pyrophosphohy-
drolase and converts noncanonical purine (d)NTPs, such
as (deoxy)inosine 5′-triphosphate ((d)ITP), into their
corresponding nucleoside monophosphate ((d)NMP); re-
leasing pyrophosphate (PPi) [8] (Fig. 1). Noncanonical
purine (d)NTPs spontaneously arise in cells. In the pur-
ine biosynthesis pathway, phosphorylation of inosine
5′-monophosphate (IMP), a precursor to adenosine 5′-
monophosphate (AMP) and guanosine 5′-monopho-
sphate (GMP), can produce both ITP and dITP [9, 10].
Additionally, oxidative deamination of adenine contain-
ing nucleosides/nucleotides or deamination of guanine
containing nucleosides/nucleotides results in the for-
mation of inosine containing nucleosides/nucleotides
[11]. In general, evidence supports that ITPase, and its
orthologs, prevent the accumulation of noncanonical
purine (d)NTPs and are conserved throughout the
three domains of life and are even found in viruses [2–
4, 12–16]. Research with bacterial, yeast and murine
systems has demonstrated that ITPase deficiency and/
or polymorphism can result in sensitivity to noncanoni-
cal purines, increased mutation rates, delayed cell cycle
progression, DNA damage and chromosomal abnor-
malities such as double-strand breaks [17–21].
ITPase is expressed in all major adult human tissues
[5]. Results from Northern blot and cDNA microarray
data indicate the highest expression is in the heart, liver,
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thyroid and thymus [5]. Likewise, mouse Itpa is
expressed in all major tissues, however the highest ex-
pression levels were found to be in the testis, brain and
thymus [22]. Mouse Itpa expression is driven by a
TATA-less promoter which has characteristics that
suggest it is a ubiquitously expressed housekeeping
gene whose expression can be amplified under certain
conditions [22].
Studies in a mouse model suggest that the role of
ITPase is highly pronounced in cardiac tissues [6]. Car-
diomyopathy in ITPase knock-out mice appears to result
from the accumulation of ITP in the nucleotide pools
and subsequent utilization of the contaminated pool.
Analysis of the nucleotide content of total heart RNA re-
vealed high levels of IMP which were roughly equivalent
to 1 % of the AMP level whereas IMP was undetectable
in wild-type total RNA samples [6]. Similarly, increased
levels of dIMP were observed in DNA harvested from
embryos deficient in ITPase [18]. The structural similar-
ities between adenine, guanine and hypoxanthine (hypo-
xanthine is the nucleobase of ITP) (see Fig. 2), make it
plausible that ITP can act as an improper substrate and
replace canonical nucleotides in some processes. One
study has shown that actomyosin binding of ITP in place
of ATP reduces the shortening velocity and rate of force
recovery and results in disordered striation during acti-
vation [23]. Therefore, an increase in ITP levels could
affect actomyosin function, leading to disorganization of
sarcomere structure in the developing heart. It is likely
that the accumulation of (d)IMP in heart nucleic acids
leads to the production of DNA lesions, defective pro-
teins, nonfunctional RNAs and reduced cell proliferation
[6, 18]. Because organ development among mammals is
very similar [24], these observations should be highly
relevant to humans. The critical role for ITPase in the
heart is underscored by the observation that the heart is
among the four tissues with the highest ITPA expression
in humans [5].
For any cell in any organism one can imagine that
genetic polymorphism could modulate purine metabol-
ism and alter the amount of: hypoxanthine entering the
purine salvage pathway, IMP produced from de novo
purine biosynthesis, or phosphorylation/reduction of
IMP to (d)ITP [25]. In any of these cases, proper func-
tion of ITPase would be vital to insure that inosine is ex-
cluded from the nucleic acids and nucleotide pools.
Concurrent polymorphism in ITPase may lead to pleio-
tropic outcomes such as DNA damage, interference with
gene expression and RNA function, and altered activity
for nucleotide binding proteins [6, 17]. Additionally, it is
possible that conditions which exacerbate nitrosative
stress, such as inflammation, would result in increased
deamination of adenine and guanine containing nucleo-
sides and nucleotides; resulting in increased concentra-
tions of (d)ITP [26]. Support for these ideas stem from
data we published in 2012 showing that perturbation of
purine metabolism in Escherichia coli leads to substan-
tial incorporation of (deoxy)inosine in nucleic acids [17].
Furthermore, an association between ITPA polymorph-
ism and mitochondrial dysfunction has been reported,
suggesting nucleotide imbalances may alter mitochon-
drial function [27]. Altogether, ITPase is an essential
protector of homeostasis in the cell, and most likely
reduces the occurrence of genome instability, cancer,
ageing, and disease in humans.
Below I will summarize several recent studies concern-
ing ITPase biochemistry and clinical outcomes associ-
ated with ITPA polymorphism or mutation. The goal of
this review is to: (1) strengthen the connection between
basic science and clinical studies; (2) summarize the
many disparate clinical outcomes that have recently
been linked to ITPA polymorphism/mutation; (3) argue
in favor of viewing ITPA variation as a disease spectrum;
and (4) suggest rationale for modulation of ITPase activity
in an effort to reduce the number of negative outcomes
for ITPA-related disease.
Fig. 1 ITPase reaction scheme
Fig. 2 Structure of purine bases. Hypoxanthine is the nucleobase of inosine
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Biochemistry
ITPase is a pyrophosphohydrolase that excludes nonca-
nonical purines from the (d)NTP pools by hydrolyzing
the acidic anhydride bond between the alpha and beta
phosphates of the incoming (d)NTP (Fig. 1) [8, 28, 29].
A key step in the enzyme mechanism appears to be sub-
strate binding, and ITPase only has high affinity for
NTPs containing noncanonical purines (ITP, dITP and
xanthosine 5′-triphosphate) [2, 5, 8]. Tight binding of
the noncanonical nucleobase in the nucleobase binding
pocket of the enzyme allows proper alignment of distal
catalytic residues to catalyze hydrolysis of the phosphoan-
hydride bonds, while interactions with NTPs containing
canonical bases result in improper alignment of the pro-
posed catalytic residues and the scissile phosphoanhydride
bond, and a much lower rate of catalysis [2–4].
ITPase is an α/β homodimeric protein [4]. Each mono-
mer consists of 194 amino acid residues and the protein
forms a 45 kDa dimer [5]. The protein has a central
elongated mixed β-sheet which forms a platform to sup-
port two globular lobes [4]. ITP binds in a cleft, between
the lobes, adjacent to the dimer interface. The specificity
pocket is buried deep within the dimerization lobe of
each monomer while the catalytic site is toward the per-
iphery, close to the dimer interface in the N-terminal lobe
[4]. Catalysis requires Mg2+ [28, 30], and is thought to
occur via acid-base chemistry [3, 4], although the specific
mechanism has not been elucidated. Maximal activity has
been observed with alkaline pH and in the presence of
reducing agent such as dithiothreitol (DTT) [5, 28] (see
reference [7] for a review of biochemical studies).
ITPase does not discriminate between the ribose and
deoxyribose carbohydrate moiety, and hydrolyzes phos-
phoanhydride bonds in noncanonical NTPs and dNTPs
with equal activity [2, 5]. One study has reported strong
positive cooperativity for the E. coli ITPase ortholog,
RdgB [13], however, cooperativity has not been reported
elsewhere. Human ITPase is competitively inhibited by
inosine 5′-diphosphate, but not NMPs or any nucleoside
tested [8]. Interestingly, strong substrate inhibition
has been observed in multiple studies using purified
ITPase in the presence of elevated levels of ITP or
dITP [2, 5, 28]. The enzyme has also been shown to
be inhibited by Cd2+, Co2+ and Ca2+ ions [29].
ITPase has been studied for over 40 years [28], how-
ever, the mechanism employed by ITPase to discriminate
between canonical and noncanonical (d)NTPs is not
fully understood. X-ray crystal structures of the protein-
substrate complex have been solved [3, 4], and several
evolutionarily conserved residues have been shown to
govern substrate selectivity [31], but rigorous bio-
chemical validation of the predictions have not been
performed. The ITPase substrate specificity pocket is
shown in Fig. 3.
An initial site-directed mutagenesis screen of the sub-
strate specificity pocket supported several assertions
based on the crystal structure [4, 31]. Experimental de-
sign of this screen allowed differences in specific activity
to reflect differences in KM and provide surrogate mea-
surements of substrate binding [31]. Based on these
measurements it seems that ITPase favors NTPs con-
taining electronegative atoms at the 6-position, such as
ITP and GTP over NTPs containing electropositive
atoms such as the 6-position amine of ATP. Indeed, x-
ray crystallography data suggest that three binding
pocket residues have potential for making favorable
hydrogen bonding interactions with the electronegative
6-postion carbonyl of ITP or GTP [4], however, biochem-
ical data indicates Arg-178 as the most crucial residue for
this discrimination [31]. X-ray data places Arg-178 within
3 Å (hydrogen-bonding distance) of both the 6-positon
carbonyl oxygen and 7-position ring nitrogen atoms of the
nucleobase in ITP. In this position Arg-178 would form
favorable hydrogen bond interactions with ITP or GTP,
but not ATP, which may account for its essential role in
ITP detoxification and substrate selectivity [4]. Add-
itionally, mutation of Arg-178 to alanine, or even the
conservative arginine to lysine substitution (R178K),
prohibits complementation of ITPase defects in E. coli
in two in vivo tests. Hence, Arg-178 has been classified
as essential for ITPase activity [31]. A substitution to
cysteine at this position was identified in a patient
Fig. 3 Model of ITPase substrate binding pocket. CPK coloring. Hx,
hypoxanthine base of inosine; R, sugar (ribose) ring. Dashed lines
indicate putative hydrogen bonds. Image reproduced from
reference [31] with permission
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suffering from infantile encephalopathy [32] and will be
discussed below.
The ITPase nucleobase binding pocket adopts a topog-
raphy that is exquisitely complementary to the incoming
hypoxanthine base of ITP [3, 4]. While the mechanism
for discrimination against adenine containing nucleo-
tides lies primarily in hydrogen bonding capacity, dis-
crimination against guanine containing NTPs appears to
be governed by steric hindrance [4, 31]. Phe-149 is the
major determinant for excluding GTP from the binding
pocket. Mutation to alanine results in a roughly 6-fold
increase in hydrolysis of GTP, and a lower level of com-
plementation for ITPase defects in E. coli. Phe-149 is po-
sitioned in close proximity to the 2-positon ring carbon
of the nucleobase. In GTP, this position is bonded to an
exocyclic amine, which is absent in ITP. Thus Phe-149
actively excludes GTP from entering the binding site,
and prevents proper alignment of the catalytic residues
with the scissile phosphoanhydride bond [4, 31]. Overall,
site-directed mutation experiments indicate that modifi-
cations which cause slight enlargements of the nucleo-
base binding site, reduce the level of discrimination
afforded by the enzyme.
To date, ITPase biochemistry remains understudied;
however, some advances have been made concerning
substrate selectivity [31] and a clinically relevant variant
[33–35]. Knowledge gaps exist in the biochemical under-
standing of ITPase and its specific role in purine metab-
olism [36]. For example, it is unknown if ITPase has
protein-binding partners, if the enzyme is posttransla-
tionally modified, or if it is allosterically regulated. Add-
itionally, the role of substrate inhibition [2] in cellular
function is vastly unknown and may serve to modulate
the intracellular concentration of ITP, IMP or even in-
osine. Support for this idea lies in the discrepancy
among data obtained from assays using either purified/
recombinant ITPase or whole-cell extracts. For example,
Bakker et al. found that ITPase is not subject to
substrate inhibition when erythrocyte cell extracts are
used as the protein source [37], whereas enzymology
studies using purified/recombinant ITPase as the source
of protein reported substrate inhibition [2, 5, 28]. Taken
together, these results hint that the level of substrate in-
hibition for ITPase may be modulated in vivo. Overall, a
better understanding of substrate inhibition may serve
as a fruitful avenue for therapeutic modulation of ITPase
activity (see below). Importantly, for one clinically signifi-
cant variant, c.94C >A (p.Pro32Thr), a clear biochemical
rationale for decreased enzyme activity is known (see
below) [33–35].
Clinically relevant ITPA variants/mutants
Over the last decade the pharmacogenetic significance
of ITPA variation has been established. In humans, at
least thirty polymorphisms have been identified in the
ITPA gene [32, 38–44]. To date, seven of the variants
have been shown to be clinically relevant (see Table 1)
[32, 40–42, 44]. Multiple reports have demonstrated that
ITPA status affects outcomes of hepatitis C treatment
[45, 46] and thiopurine therapy [36, 47]. Additionally,
ITPA mutation has been shown to cause early infantile
encephalopathy [32] and variation has been linked to
young-onset tuberculosis susceptibility [44]. Therefore,
the spectrum of phenotypes related to ITPA status is full
range and spans improved therapeutic outcomes to in-
fantile death.
In 2004 it was estimated that about 5 % of the world
population harbors the c.94C > A (p.Pro32Thr) ITPA
variation with the highest penetrance, 14 to 19 %, in
Asian populations [48]. Since then several more poly-
morphisms have been identified [32, 40, 44] (see Table 1)
and recent reports suggest that nearly a third of the
population may harbor ITPA polymorphism that is asso-
ciated with decreased ITPase activity [49–51]. In fact,
even heterozygous variation which results in overall
ITPase activity that is 60 % of the homozygous wild-type
Table 1 Clinically relevant ITPA polymorphism
Location SNP ID variation biological significance Clinical
significance
Reference
c.94C > A (p.Pro32Thr) rs1127354 SNP reduced expression, stability, catalysis ADR [40]
c.124 + 21A > C rs7270101 SNP poor splicing efficiency ADR [40]





rs863225424 duplication Frameshift, nonfunctional protein encephalopathy [32]
c.452G > A (p.Trp151Stop) NA nonsense Nonsense RNA-mediated decay encephalopathy [32]
c.532C > T (p.Arg178Cys) NA SNP Altered substrate specificity, poor solubilitya encephalopathy [32], NEBa
g.19176G > A rs13830 SNP 3′UTR variation; altered mRNA metabolism/
translation
TB susceptibility [44]
ADR adverse drug reaction, NA not available
aunpublished results
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level can be clinically significant [49, 51–54], however,
pathological mutations are very rare [32].
Genotype status can result in a varying degree of re-
duction in ITPase activity. Most studies have focused on
ITPase activity in erythrocytes for the more common
polymorphisms, c.94C > A (p.Pro32Thr) and c.124 +
21A > C, and the results between studies are in good
agreement [38–40]. For example, in Caucasian popula-
tions, the c.94C > A (p.Pro32Thr) polymorphism results
in severe reduction of ITPase activity and the mean ac-
tivity for heterozygous individuals is about 25 % of the
wild-type levels while homozygous individuals retain less
than 1 % of the wild-type levels [39]. The c.124 + 21A >
C variant results in a more moderate reduction in
ITPase activity, and heterozygotes retain about 60 % of
the wild-type levels while homozygous individuals retain
about 30 % of the wild-type levels. Consequently,
c.94C > A (p.Pro32Thr) and c.124 + 21A > C compound
heterozygosity results in severe reduction of ITPase ac-
tivity and these individuals retain about 8 % of the wild-
type levels [39]. It is important to underscore that these
data are obtained from erythrocytes, and that the level
of activity observed may be different for different cell
types within the same individual.
ITPA variation/mutation: effects on protein structure and
expression
Clinically relevant ITPA variants are listed in Table 1. Of
the seven variants, four are single nucleotide substitu-
tions, one a nonsense mutation, along with a duplication
and a deletion. The later three instances are very rare
and can be considered mutations as opposed to variants.
These three mutants were identified in a cohort of
homozygous patients suffering from infantile encephal-
opathy [32]. These mutants are predicted to have the
greatest effect on protein structure/function by changing
the length of the 194 residue protein and most likely re-
sult in a nonfunctional protein. The nonsense mutation
(c.452G >A) introduces a premature stop codon at amino
acid position 151, resulting in a C-terminal truncated pro-
tein, which would lack the highly conserved specificity
pocket containing the SHR signature sequence at positions
176–178. For the duplication mutant (c.359_366dupTCAG-
CACC), an 8 bp duplication is introduced which results in
a frameshift starting at amino acid positon 123. This muta-
tion is predicted to produce a 225 amino acid polypeptide
with altered amino acid sequence. Concerning the deletion
mutation (c.264-607_295 + 1267del), a deletion of 1,874
base pairs was identified which completely spans exon 5
and is predicted to result in an out of frame transcript.
ITPase activity in erythrocyte or fibroblast cells derived
from patients homozygous for each of these three muta-
tions was severely diminished, indicating significant loss of
activity for the protein [32].
Of the four single nucleotide variants/mutants that are
clinically relevant, two affect protein structure. Among
these the c.94C > A (p.Pro32Thr) variant is the most
studied. This common point mutation is thought to
affect the protein in three different ways: decreased ex-
pression of the full length transcript, reduced catalytic
activity and decreased stability [33–35, 55]. This vari-
ation has been shown to alter mRNA splicing events
such that exon 2 and 3 are misspliced; an activity which
presumably results in a nonfunctional protein. While
this missplicing event happens in wild-type cells to some
extent, the level of missplicing increases over three-fold
for homozygous variants [55]. Additional studies have
shown that substitution of proline with threonine at pos-
ition 32 results in a protein with nearly two-fold less
catalytic activity and reduced stability [33–35]. This pos-
ition in the polypeptide chain is located in an exterior
loop that is adjacent to the protein-dimer interface and
close to residues that are thought to be involved in en-
zyme catalysis [3, 4]. Proline at this position is thought
to have a role in restricting flexibility of the external
polypeptide chain, which reduces ability of solvent to
infiltrate the protein interior and helps maintain proper
positioning of catalytic residues [33, 34]. Hence, this
single nucleotide polymorphism (SNP) results in poor
expression of an unstable, catalytically compromised
protein.
The c.532C > T (p.Arg178Cys) mutant is very rare and
has been recently identified in a patient suffering from
infantile encephalopathy [32]. Arg-178 is a highly con-
served position in the ITPase structure and is one of the
residues that form the SHR signature sequence for
ITPase. It is thought to have a major role in substrate se-
lectivity as it is postulated to interact with the nucleo-
base of incoming (d)ITP at two positions [4] (see above).
This particular variant has been predicted to result in a
nonfunctional protein by multiple software programs
[32]. Additionally, a site-directed mutagenesis study has
identified this position as essential for ITPase activity
both in vitro and in vivo [31].
The two additional single nucleotide variants do not
affect protein structure. The common c.124 + 21A > C
variant is an intronic substitution that prevents the ca-
nonical spliceosome reaction [55]. Substitution of aden-
ine at this position is thought to destroy the preferred
branch point in the splicing reaction, resulting in an
alternative splicing event that is less efficient, therefore
reducing expression of the ITPA gene [55]. The recently
identified g.19176G > A variant is also thought to alter
ITPA expression [44]. This particular variant is located
in the 3′-untranslated region (3′-UTR) of the ITPA tran-
script. It has been hypothesized that this variant affects
mRNA metabolism and/or translation resulting in a
higher level of ITPase expression [44].
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Clinical effects of ITPA variation/mutation
Role of ITPase in drug metabolism
ITPase is thought to have a direct role in metabolism of
thiopurine drugs [36]. Thiopurines such as azathioprine
and 6-mercaptopurine are prodrugs and require enzym-
atic bioactivation to undergo ribosylation and phosphor-
ylation to become the active nucleotide form. In the
active form, thiopurines are antimetabolites which act by
replacing guanosine containing nucleotides in physio-
logical processes. Hence, thiopurines can disrupt mul-
tiple biologic pathways such as DNA and RNA
metabolism, purine metabolism, and stimulate pro-
apoptotic pathways (see references [56, 57] for review).
One intermediate in this pathway, 6-thio-inosine 5′-tri-
phosphate (6-TITP), has a structure nearly identical to
ITP (see Fig. 4 for comparison of nucleobases). 6-TITP
has been shown to be a substrate for ITPase [36]. This
result suggests that the drug may enter a futile cycle of
phosphorylation by kinase enzymes to the triphosphate
form, and hydrolysis by ITPase back to the monopho-
sphate form. Therefore, the end result is that the ITPase
enzyme acts to reduce an intermediate in the pathway,
and subsequently the amount of active form of the drug
present in human cells (Fig. 5a).
Ribavirin is also activated by intracellular kinases to
form a nucleoside triphosphate (Fig. 5b) [52, 58]. In this
case, the ribonucleoside triphosphate becomes a sub-
strate for the replicative RNA-dependent RNA polymer-
ase and it is incorporated into the viral genome.
Incorporation into the viral genome is thought to lead to
chromosomal degradation and a reduced viral load for
the host. To date, ITPase has not been demonstrated to
have a direct role in ribavirin metabolism (although evi-
dence suggests it may [50]), however it is thought to
modulate overall nucleotide pools and ITPA status can
affect treatment outcomes as discussed below [52].
ITPA variation affects outcome of thiopurine treatment
Several groups have shown that ITPA variation corre-
lates with increased toxicity to thiopurines [53, 54, 56,
59–61]. Thiopurine therapy is widespread. Thiopurines,
such as azathioprine or 6-mercaptopurine, are immuno-
suppressants that are commonly administered to organ
transplant recipients [62], and patients undergoing treat-
ment for inflammatory bowel disease [63], ulcerative col-
itis [64], Crohn’s Disease [65] and a variety of cancers
[66–68]. For patients harboring ITPA variation, common
side effects included rash, flu-like symptoms, pancrea-
titis, life threatening myelosuppression, and hepatotox-
icity. Toxicity presumably occurs due to an increase of
thiol-containing NTPs. Because these side effects can be
quite devastating to the patient, dosage alteration or dis-
continuation of treatment is common for individuals
with ITPA polymorphism [53, 59] (see references [36,
56, 57] for review). As a result, researchers have sug-
gested including pre-therapeutic screening of patients
for ITPA polymorphism to minimize the occurrence of
drug toxicity [69–71]. Importantly, not all ITPA poly-
morphism is associated with thiopurine toxicity. For
example, one group found that heterozygosity for the
c.94C > A (p.Pro32Thr) allele was associated with ad-
verse drug reactions, but both hetero- and homozygosity
for the c.124 + 21A > C allele was not [59].
An alternative approach to alleviating thiopurine toxicity
is to prescribed 6-thioguanine in place of azathioprine or
6-mercaptopurine. Bioactivation of 6-thioguanine pro-
ceeds via a thio-GMP intermediate (6-TGMP), rather than
a thio-IMP intermediate (6-TIMP), thus by-passing the
ITPase reaction (see Fig. 5a) [59]. Substitution with
6-thioguanine has been used successfully in a cohort
of Crohn’s disease patients who demonstrated resist-
ant to 6-mercaptopurine therapy [72].
One caveat to the involvement of ITPase in thiopurine
toxicity is that some studies have not found a correlation
between ITPA variation and thiopurine toxicity [73–76].
The conflicting data underscores the fact that many dif-
ferent gene products have a role in thiopurine metabol-
ism (at least 20), and phenotypic variation among
patients may mask effects of ITPA variation in certain
studies [70]. Indeed, studies that do not find a correl-
ation between ITPA variation and drug toxicity identify
small sample size, ethnicity, drug interactions and the
retrospective nature of their studies as shortcomings [73,
74, 76, 77]. In 2014, Matimba et al. used a “three-tiered”
experimental strategy to overcome some of the short-
comings associated with clinical studies. This allowed
Fig. 4 Comparison of relevant nucleoside/nucleotide structures. Ribavirin is bioactivated to the triphosphate form; inosine is an intermediate in
purine metabolism; 6-TIMP (6-thio-inosine 5′-monophosphate) is an intermediate in thiopurine bioactivation
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them to positively identify and functionally validate an
association between ITPA variation and an altered thio-
purine response phenotype [70].
ITPA variation affects outcome of hepatitis C treatment
In 2010 and following studies, the c.94C > A
(p.Pro32Thr) variant was shown to delay the develop-
ment of anemia in patients treated for chronic hepatitis
[52, 78, 79]. For the 170 million people affected with
hepatitis C worldwide, one of the potential side effects
for the standard treatment of pegylated interferon alpha
and ribavirin is hemolytic anemia [80]. In a follow up
study, researchers found that individuals harboring ei-
ther the c.94C > A (p.Pro32Thr) or c.124 + 21A > C vari-
ations not only had delayed development of anemia, but
also had a decreased need for ribavin dose reduction
[51]. Recently, methods have been developed to use
ITPase activity as an accurate predictor for the develop-
ment of anemia during ribavirin treatment [81]. Based
on these findings, it has been suggested that status of
the ITPA locus, or ITPase activity, should be considered
for patients beginning hepatitis C therapies which in-
clude ribavirin [51, 81–83]. In fact, an ITPA SNP-based
index has been developed to advise healthcare workers
in maximizing the tolerability of treatment regimen for
patients with chronic hepatitis C [84].
While the mechanism for the protective effect of ITPA
polymorphism is under debate, it seems likely that
modulation of nucleotide pools plays a role. Ribavirin-
induced anemia is thought to result from decreased
erythrocyte ATP levels, which in turn affects ATP-
dependent oxidative metabolism [85] and reduces the
levels of GTP in the cell [25]. However, it has been specu-
lated that for individuals with reduced ITPase activity, a
rise in intracellular ITP concentrations might allow ITP to
replace GTP as a cosubstrate for the adenylosuccinate
synthetase reaction, thus allowing ATP biosynthesis to
continue [25]. The rise in ATP levels subsequently allows
GTP biosynthesis to continue. Therefore, an increased
ITP concentration may allow erythrocyte nucleotide pools
to maintain a more normal level which lowers the inci-
dence of hemolytic anemia [86]. One caveat to this hy-
pothesis is that adenylosuccinate synthetase activity has
not been demonstrated in erythrocytes [81].
The mode of action of ribavirin requires bioactivation
to the nucleotide ribavirin 5′-triphosphate (RBV-TP),
which is subsequently incorporated in the viral genome
and interferes with replication [52, 58]. Individuals with
variant ITPA phenotypes have increased levels of RBV-
TP in their red blood cells [50]. Importantly, the level of
RBV-TP in cells corresponded to ITPA status, i.e. geno-
types predicted to have lower ITPase activity had greater
levels of RBV-TP [50]. Ribavirin has an electronegative
oxygen (carbonyl) in approximately the same location as
the 6-position carbonyl in inosine [31] (see Fig. 4). Taken
together, it is likely that RBV-TP is a substrate for
ITPase, but this has not been directly demonstrated in
the current literature.
Fig. 5 Pathways for drug bioactivation and drug degradation by ITPase. a Thiopurine metabolism. Based on [7, 36]. b Ribavirin metabolism. AZA:
azathioprine; 6-TG, 6-thioguanine; 6-MP: 6-mercaptopurine; 6-TIMP, 6-TIDP, 6-TITP: 6-thio-inosine 5′-mono-, di- and tri-phosphate; 6-TGMP, 6-TGTP:
6-thio-guanosine 5′-mono- and tri-phosphate; 6-Me-TIMP, 6-Me-TITP: 6-methylthio-inosine 5′-mono- and tri-phosphate. RBV: ribavirin; RBVMP, RBVDP,
RBVTP: ribavirin 5′-mono-, di- and tri-phosphate; HGPRT: hypoxanthine-guanine phosphoribosyltransferase; TPMT: thiopurine S-methyltransferase; NMPK,
NDPK: nucleoside mono- and di-phosphate kinase; ADK: adenosine kinase
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Overall, it appears that ITPA variation would alter the
monophosphate to triphosphate ratio of ribavirin con-
taining nucleotides. Consequently, it is possible that the
mechanism for the observed delay in onset of anemia
for patients with ITPA variation may involve a reduction
in the level of the monophosphate form, or an increase
in the level of the triphosphate form of ribavirin. Fur-
thermore, the role of nucleoside diphosphate kinase
should be considered. This enzyme is active in erythro-
cytes [87] and its reversible and promiscuous ping-pong
mechanism essentially allows any NTP to provide the
phosphorylation power to quickly convert any NDP into
its corresponding NTP [25]. Therefore, in the case of
ITPA variation, the rise in ITP and RBV-TP levels is ex-
pected to contribute to the pool of ATP equivalents in
the cell.
ITPA variation has also been associated with reduced
relapse risk and achieving sustained virological response
(SVR) for hepatitis C patients [49]. Rembeck et al. found
that for patients receiving a conventional 800 mg daily
ribavirin dose and peginterferon-2α, those that had an
ITPA status which was predicted to result in ITPase ac-
tivity that was 60 % or less than wild-type, both relapse
rate and SVR were favorably impacted. Importantly, the
researchers observed no statistical difference in
hemoglobin levels among patients achieving or not
achieving SVR, suggesting that protection against onset
of anemia is not related to an improved rate of SVR. For
patients harboring ITPA variation, the authors suggested
that imbalances in the NTP pools such as increased
levels of ITP, along with decreased levels of GTP (due to
inhibition of inosine monophosphate dehydrogenase by
ribavirin) may result in increased incorporation of ITP
into the viral genome. In turn, the increased level of in-
osine in viral RNA may trigger reduction of the viral
load via an innate immune response [49].
ITPA mutation causes infantile encephalopathy
Kevelam et al. recently identified recessive ITPA muta-
tion as a cause of early infantile encephalopathy [32].
The researchers used magnetic resonance imaging
(MRI) and whole exome sequencing (WES) to link very
rare, recessive mutation of the ITPA gene to a unique
MRI pattern. Seven patients were identified who pre-
sented severe progressive microcephaly, seizures and de-
velopmental delays shortly after birth. Sadly, six of the
seven patients died before 2.5 years of age. Cardiac ab-
normalities and severely reduced erythrocyte and fibro-
blast ITPase activity was observed, but purine and
pyrimidine urine profiles were normal [32]. These phe-
notypes are consistent with high levels of brain and car-
diac ITPA expression [5]. The homozygous genetic
variation observed included gene deletions, as well as
nonsense, frameshift and missense mutations [32]. All
but the latter was predicted to significantly alter the pri-
mary structure of the resulting protein. In the case of
the missense mutation, a nonfunctional protein with a
substitution of Arg-178 with cysteine was predicted. An
R178C substitution would alter a key residue in the sub-
strate specificity pocket and this substitution is predicted
to affect the ability of this residue to hydrogen bond
with the 6-position keto oxygen of ITP (see above and
Fig. 3) and would most likely reduce affinity for ITP
[32]. Alternatively, because this point mutation intro-
duces an additional cysteine residue into the primary
protein structure, it is possible that improper disulfide
bonds could form with one of the seven other cysteine
residues during protein maturation. Perusal of x-ray
crystallographic data [4] suggests that native ITPase qua-
ternary structure does not contain any disulfide bonds,
however, position 178 is in close proximity to Cys-116 in
a neighboring beta strand (personal observation). Pre-
liminary work with the R178C mutant ITPase indicates
this protein has a low level of solubility when overex-
pressed in E. coli cells (unpublished data), however the
occurrence of disulfide bond formation is not known.
Because ITPase has been shown to be activated with
DTT [5, 28], it is possible cysteine redox chemistry has a
role in the enzyme structure and/or chemistry.
ITPA variation affects onset of tuberculosis
Recently, the ITPA gene has been identified as a suscep-
tibility gene for young-onset tuberculosis (TB) [44].
Here, the researchers used next-generation sequencing
(NGS) to identify single nucleotide polymorphisms in
young TB patients from multi-case families and found
two ITPA polymorphisms (g.19176G > A and c.94C > A
(p.Pro32Thr)) to be associated with young TB patients.
The g.19176G > A variant showed the strongest associ-
ation. This variant is located in the 3′-UTR of the ITPA
gene and it is hypothesized to modulate ITPA expression
at the posttranscriptional level. In silico eQTL analysis
using lymphoblastoid expression profile data indicates
an increased level of expression for the minor 'A' allele
form of this variant. Subsequently, it was hypothesized
that a lower level of expression for the major 'G' allele
may render individuals harboring this allele more
susceptible to TB infection. Similarly, c.94C > A
(p.Pro32Thr) polymorphism, which would cause re-
duced ITPase activity (see above), is also linked to in-
creased susceptibility. Considering that the thymus is
among the human tissues with highest ITPA expres-
sion [5], these results suggest that ITPase may have a
role in the host immune system upon onset and pro-
gression of TB [44]. Therefore, this study introduces
the idea that overexpression of the ITPA gene may
have a protective effect.
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A disease spectrum for ITPA variation
Vanderheiden first identified patients with an abnormal
accumulation of erythrocyte ITP in the 1960s and sug-
gested that these patients were ITPase deficient [88, 89].
In 2002 a report indicated that erythrocytes from
c.94C > A (p.Pro32Thr) homozygous individuals showed
0 % ITPase activity, and, it was noted that there ap-
peared to be no biological consequence of this absence
[40]. Today it is clear that ITPase has an essential role in
purine metabolism [32]. This is underscored by the fact
that ITPase is so highly conserved among all branches of
biology [12], and expressed in all mammalian tissues
assayed [5]. The role of the protein in specific tissues ap-
pears to differ and measurement of activity in one spe-
cific tissue does not necessarily reflect activity of the
whole organism. For instance, one study determined that
low erythrocyte ITPase activity did correlate with lower
activity in white blood cells and platelets, but the overall
level of activity was considerably higher for these cells
[90]. Over time, more and more reports revealed signifi-
cant relationships between ITPA variation and altered
drug regimen outcomes [52, 59–61, 78, 79]. Today, with
two examples of lethality due to severe homozygous
ITPA defects (Itpa knockout mouse data [6] and infant-
ile encephalopathy data [32]), along with an example of
increased fitness due to potential ITPA overexpression
(TB susceptibility data [44]), it seems more likely that
there is a spectrum of ITPA-related disease as Kevelam
et al suggested [32]. Hence, most ITPA variation results
in modulated ITPA expression/activity, rather than ab-
sence of ITPase, therefore, use of term “ITPase defi-
ciency” in the literature to describe the majority of ITPA
polymorphism appears to be a historical inaccuracy.
Future directions
Considering that the current data indicates the pheno-
typic spectrum of ITPA defects ranges from mild drug
toxicity to infantile death, it seems likely that therapies
will emerge to modulate ITPase activity. Advances in
DNA sequencing techniques, such as WES and NGS,
and reduced cost of sequencing is likely to identify an in-
creased number of instances where ITPA status contrib-
utes to neurological and cardiac disease as well as
complications associated with inflammation, the immune
system or other unknown ITPA-related diseases. Given
the widespread use of thiopurines, and magnitude of indi-
viduals infected with hepatitis C, while considering that
roughly one third of the world population has ITPA poly-
morphism, it seems plausible that development of these
therapies will be met with considerable need.
Above, I have outlined examples where ITPA poly-
morphism/mutation is detrimental to patient outcomes
(thiopurine toxicity/infantile death) and examples indi-
cating that ITPA polymorphism is beneficial to patient
outcomes (reduced anemia in hepatitis C patients,
young-onset TB). Current treatment for the pharmaco-
logical related conditions includes dose modification,
treatment of the side effects or discontinuation of the
drug [54, 91]. Below, I will outline strategies which have
potential to prevent the occurrence of negative out-
comes for these patients. Therefore, ITPase serves as an
interesting drug target because there is a need for both
positive and negative modulation.
Positive modulation of ITPase activity
With the development of improved gene delivery sys-
tems, and gene editing tools one can envision a day
when a bioengineered ITPase (with increased activity
and improved substrate discrimination) or gene editing
system (to enhance/correct ITPase function), can be de-
livered to a patient suffering from cardiac or neuro-
logical maladies due to very rare and severe mutation, or
even possibly patients suffering from thiopurine toxicity
due to common polymorphism. In the cell, this scenario
would exacerbate existing ITPase activity and cause a
much greater increase in specificity for (d)ITP or 6-
TITP over the canonical (d)NTPs, thus reducing time
spent with the unproductive binding and catalysis of ad-
enine and guanine containing nucleotides. In E.coli cells,
ITP levels are about 200 μM, whereas ATP and GTP are
approximately 50- and 25-fold greater, respectively [92].
KM values for ITPase with these substrates follow the
same trend [2, 12]. Therefore, alteration of kinetic con-
stants via protein engineering should result in improved
ability of ITPase to discriminate between canonical and
noncanonical purine containing nucleotides. This is ex-
pected to greatly enhance the ability of the enzyme to
clear cells of excess (d)ITP or drug metabolite.
Towards this goal, we have identified three gain-of-
function mutants [31]. Most notably, the E22A mutant
shows a nearly two-fold enhancement in ITP hydrolyz-
ing activity compared to wild-type, with a two- and five-
fold decrease in hydrolyzing activity with GTP and ATP,
respectively, compared to wild-type. Overall, we observe
a roughly 10-fold enhancement over wild-type for dis-
crimination between ITP and ATP. X-ray crystallography
data suggests Glu-22 does not directly interact with the
incoming nucleotide [4], but rather has an organizing
role in the specificity pocket such as orienting the essen-
tial Arg-178 as discussed above (Fig. 3). Unfortunately,
this protein has reduced stability in vivo and cannot
complement ITPase defects in E. coli. Similarly, the
K172A mutant exhibits a two-fold increase in ITP
hydrolyzing activity and a greater than two-fold decrease
in ATP or GTP hydrolyzing activity. In vivo, this mutant
is more stable than the E22A mutant and it does have
an ability to partially complement ITPase defects in E.
coli [31]. Detailed biochemical and modeling data with
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these mutants will provide a platform for protein engin-
eering experiments to continue improving ITPase activ-
ity and/or substrate discrimination with the aim of
developing therapies to reverse thiopurine toxicity,
neurological disorders, TB susceptibility and emerging
ITPA-related disorders in patients affected by ITPA
polymorphism.
In the case of the c.94C > A (p.Pro32Thr) ITPase, a
portion of the reduction in enzyme activity has been at-
tributed to reduced protein stability and rate of catalysis
[33–35] (see above). This substitution affects an exterior
loop of the protein, and substitution with an amino acid
that does not have a tertiary peptide amine, renders the
loop more flexible. Therefore, it has been speculated
that a small molecule could be designed which would
bind to this region of the protein and help stabilize
this exterior loop [7].
Negative modulation of ITPase activity
Because reduced ITPase activity results in improved out-
comes for patients undergoing ribavirin treatment [52],
it is plausible that competitive ITPase inhibitors could
be developed to help reduce anemia in individuals not
affected by ITPA polymorphism. Therefore, molecules
which inhibit ITPase activity are expected to have clin-
ical significance. Considering that that the substrate spe-
cificity pocket has exquisite complementarity to the
nucleobase of ITP and strongly favors electronegativity
at the 6-position [4], competitive inhibitor molecule de-
sign should focus on nucleotides or nucleobases where
the nucleobase has chemical properties similar to hypo-
xanthine. Alternatively, irreversible inhibitors could be
designed to have structures that covalently attach to res-
idues lining this pocket, or have such low dissociation
constants that they irreversibly bind to this pocket.
Because of the unique role ITPase has in the cell, the
landscape of the substrate specificity site is expected
to be unique, which would reduce the likelihood of
cross-reactivity with ATP- and GTPases. Noncleavable
substrates, such as inosine containing phosphoramidites,
may prove advantageous as well, but would have greater
difficulty entering the cell [25].
One confounding fact of ITPase biochemistry is that
substrate inhibition has been demonstrated for two
mammalian homologs with elevated concentrations of
substrate [2, 5, 28]. Although substrate inhibition was
first demonstrated over 45 years ago [28], the signifi-
cance of this mechanism remains unknown. It seems
likely this effect may be due to specific biochemical roles
for ITPase in purine metabolism in certain tissues at cer-
tain times. Currently there is at least one example which
indicates that ITPase is not subject to substrate inhib-
ition in vivo [37], suggesting that a cellular component
can reverse this phenomenon. To date this issue remains
completely unresolved in the literature. Regardless, the
effect of substrate inhibition with purified/recombinant
ITPase is strong and renders mammalian ITPase nearly
inactive when ITP concentrations are in the high micro-
molar range [2]. In fact, substrate inhibition occurs at
elevated levels of ATP (unpublished observations) and
GTP [28] as well. Overall, the possibility of negative allo-
steric binding sites should be considered when designing
small molecule inhibitors for ITPase. Design of competi-
tive and noncompetitive inhibitory molecules awaits
more rigorous biochemical characterization and molecu-
lar modelling of ITPase.
Conclusions
Recent studies demonstrate disparate examples of dis-
ease related to ITPA polymorphism/mutation. Recent
biochemical studies have begun to elucidate the mech-
anism ITPase uses to discriminate between canonical
and noncanonical purine containing NTPs, and deter-
mine the underlying mechanism of disease state. In gen-
eral, ITPase is an understudied protein and a knowledge
gap exists in the basic science of ITPase biochemistry.
Currently, seven ITPA variants/mutants are known to
affect clinical outcomes. ITPA status can have beneficial
or detrimental consequences, depending on the clinical
setting. Drug toxicity occurs in patients with ITPA vari-
ation undergoing thiopurine therapy, whereas develop-
ment of anemia in the treatment of hepatitis C is
delayed for individuals with ITPA polymorphism. The
current understanding is that these individuals retain a
functional enzyme, however, the enzyme expression is
reduced (c.124 + 21A > C), and in some cases catalysis
and stability is reduced as well (c.94C > A (p.Pro32Thr)).
To date, several preliminary reports have indicated a
need to determine ITPA status, or enzyme activity, prior
to treatment for conditions where ITPA status has been
shown to affect patient outcomes, however, no large
scale prospective cohort studies have been performed to
validate these results. ITPase enzyme activity is directly
related to ITPA status, and individuals harboring homo-
zygous ITPA variation experience the greatest effects.
Instances of mutation, where the protein length (c.264-
607_295 + 1267del1906, c.359_366dupTCAGCACC,
c.452G > A (p.Trp151Stop)) and/or functionality
(c.532C > T (p.Arg178Cys)) is grossly altered are very
rare and homozygosity results in infantile encephalop-
athy and lethality. On the other hand, ITPA variation
which is predicted to increase protein expression is
thought to reduce susceptibility to tuberculosis. Consid-
eration of these examples suggests that there is a
spectrum of ITPA-related disease. Future studies con-
cerning both positive and negative modulation of ITPase
activity will meet the needs of patients suffering from
ITPA-related disease.
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